In the present study, out findings demonstrate that inhibition of Axl, a frequently overexpressed functional RTK in many types of cancer involving in tumor malignancy and immune modulation, triggers the anti-cancer efficacy critically depending on tumor cell-extrinsic immune effector mechanisms in two highly clinical relevant murine tumor models. Here, AXL is linked to cancer.